E. Paranina, Candidate of Medical Sciences; E. Krivoshchekov, MD; P. Paranin
Samara State Medical University, Ministry of Health of Russia

The article presents a review of the literature on the relationship of peripheral artery diseases and cardiovascular complications. According to modern concepts, peripheral artery diseases are classified as markers of very high cardiovascular risk. The most important aspect of the therapy of patients in this category, in addition to correcting specific symptoms of vascular lesions of the lower extremities, is to reduce the risk of developing cardiovascular diseases and their prevention, and treatment of patients in this category should be carried out in accordance with the recommendations for secondary prevention of cardiovascular complications, the most important part of which is the control of serum lipids. Statins are the most widely used class of drugs for the correction of hypercholesterolemia, but the frequency of their appointment as a strategically important class of drugs to prevent the development of atherosclerotic cardiovascular complications in high- and very high-risk individuals in the Russian Federation, as in other countries, remains low. The basic principles of lipid-lowering therapy in patients with peripheral artery diseases are described: strategies, goals and issues of therapy control.

peripheral artery diseases
cardiovascular risk
peripheral vascular disease
cardiovascular risk.

  1. Aboyans V., Ricco J.-B., Bartelink M.-L.E.L. et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018; 39 (9): 763–816. DOI: 10.1093/eurheartj/ehx095
  2. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015; 385 (9963): 117–71. DOI: 10.1016/S0140-6736(14)61682-2
  3. Sigvant B., Lundin F., Wahlberg E. The risk of disease progression in peripheral arterial disease is higher than expected: a meta-analysis of mortality and disease progression in peripheral arterial disease. Eur J Vasc Endovasc Surg. 2016; 51: 395–403. DOI: 10.1016/j.ejvs.2015.10.022
  4. Рекомендации ЕОК/ЕОСХ по диагностике и лечению заболеваний периферических артерий 2017. Российский кардиологический журнал. 2018; 8: 164–221 [2017 ESC Guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European society for vascular surgery (ESVS). Russian Journal of Cardiology. 2018; 8: 164–221 (in Russ.)]. DOI: 10.15829/1560-4071-2018-8-164-221
  5. Степанов Н.Г. Качество жизни пациента и ее продолжительность после ампутации. Ангиология и сердечно-сосудистая хирургия. 2004; 10 (4): 13–4 [Stepanov N.G. Patient's quality of life and lifespan. Angiology and Vascular Surgery. 2004; 10 (4): 13–4 (in Russ.)].
  6. Маклакова М.П. Прогнозирование и профилактика кардиальных осложнений у больных, оперированных по поводу атеросклероза терминального отдела аорты и артерий нижних конечностей. Ангиология и сосудистая хирургия. 2003; 9 (3): 111–5 [Maklakova M.P. Prediction and prevention of cardiac complications in patients operated for atherosclerosis of the terminal aorta and lower limb arteries. Angiology and Vascular Surgery. 2003; 9 (3): 111–5 (in Russ.)].
  7. Кошкин В.М. Принципы организации специализированной ангиологической помощи в амбулаторной практике: методические рекомендации. М., 2002; с. 44 [Koshkin V.M. Printsipy organizatsii spetsializirovannoi angiologicheskoi pomoshchi v ambulatornoi praktike: metodicheskie rekomendatsii. M., 2002; s. 44 (in Russ.)].
  8. Murabito J., D'Agostino R., Silbershatz H. et al. Intermittent claudication. A risk profile from The Framingham Heart Study. Circulation. 1997; 96: 44–9. DOI: 10.1161/01.cir.96.1.44
  9. Badimon L., Vilahur G. Beneficio clinico de las estatinas: ?‘hemos cubierto todo el espectro? Rev Esp Cardiol Supl. 2011; 11: 3–13. DOI: 10.1016/S1131-3587(11)70009-7
  10. Antonopoulos A., Margaritis M., Lee R. et al. Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials. Curr Pharm Des. 2012; 18: 1519–30. DOI: 10.2174/138161212799504803
  11. Liao J., Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005; 45: 89–118. DOI: 10.1146/annurev.pharmtox.45.120403.095748
  12. Mohler E.R., Hiatt W.R., Creager M.A. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation. 2003; 108: 1481–6. DOI: 10.1161/01.CIR.0000090686.57897.F5
  13. McDermott M.M., Guralnik J.M., Pearce W.H. et al. Statin use and leg functioning in patients with and without lower-extremity peripheral arterial disease. Circulation. 2003; 107: 757–61. DOI: 10.1161/01.cir.0000050380.64025.07
  14. Vidula H., Tian L., Liu K. et al. Comparison of effects of statin use on mortality in patients with peripheral arterial disease with versus without elevated C-reactive protein and D-dimer levels. Am J Cardiol. 2010; 105: 1348–52. DOI: 10.1016/j.amjcard.2009.12.054
  15. Feringa H.H., Karagiannis S.E., van Waning V.H. et al. The effect of intensified lipid-lowering therapy on long-term prognosis in patients with peripheral arterial disease. J Vasc Surg. 2007; 45: 936–43. DOI: 10.1016/j.jvs.2007.01.024
  16. Ardati A.K., Kaufman S.R., Aronow H.D. et al. The quality and impact of risk factor control in patients with stable claudication presenting for peripheral vascular interventions. Circ Cardiovasc Interv. 2012; 5: 850–5. DOI: 10.1161/circinterventions.112.975862
  17. Kim W., Gandhi R.T., Peña C.S. et al. The influence of statin therapy on restenosis in patients who underwent nitinol stent implantation for de novo femoropopliteal artery disease: two-year follow-up at a single center. J Vasc Interv Radiol. 2016; 27: 1494–501. DOI: 10.1016/j.jvir.2016.05.037
  18. Isma N., Barani J., Mattiasson I. et al. Lipid-lowering therapy is related to inflammatory markers and 3-year mortality in patients with critical limb ischemia. Angiology. 2008; 59: 542–8. DOI: 10.1177/0003319707306144
  19. Kokkinidis D.G., Arfaras-Melainis A., Giannopoulos S. et al. Statin therapy for reduction of cardiovascular and limb-related events in critical limb ischemia: a systematic review and meta-analysis. Vasc Med. 2020; 25: 106–17. DOI: 10.1177/1358863X19894055
  20. Grundy S.M., Stone N.J., Bailey A.L. et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019; 73: e285–350 [Erratum in: J Am Coll Cardiol. 2019; 73: 3237–41]. DOI: 10.1016/j.jacc.2018.11.003
  21. Mach F., Baigent C., Catapano A.L. et al. 2019 Рекомендации ESC/EAS по лечению дислипидемий: модификация липидов для снижения сердечно-сосудистого риска. Российский кардиологический журнал. 2020; 25 (5): 3826 [Mach F., Baigent C., Catapano A.L., et al. 2019 ESC/EAS Guidelines for themanagement of dyslipidaemias: lipid modification to reduce cardiovascular risk. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Russian Journal of Cardiology. 2020; 25 (5): 3826 (in Russ.)]. DOI: 10.15829/1560-4071-2020-3826
  22. Aboyans V., Ricco J.-B., Bartelink M.-L.E.L. et al. Editor's Choice – 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg. 2018; 55 (3): 305–68. DOI: 10.1016/j.ejvs.2017.07.018
  23. Piepoli M.F., Howes A.V., Agewall et al. 2016 European guidelines for the prevention of cardiovascular diseases in clinical practice: Sixth joint task force of the European Society of Cardiology and other societies on the prevention of cardiovascular diseases in clinical practice (consisting of representatives of 10 societies and invited experts). Developed with the special participation of the European Association for Cardiovascular Prevention and Rehabilitation (EACPR). Eur Heart J. 2016; 37: 2315–81. DOI: 10.1093/eurheartj/ehw106
  24. Arya S., Khakharia A., Binney Z.O. et al. Association of statin dose with amputation and survival in patients with peripheral artery disease. Circulation. 2018; 137: 1435–46. DOI: 10.1161/CIRCULATIONAHA.117.032361
  25. Foley T.R., Singh G.D., Kokkinidis D.G. et al. High-intensity statin therapy is associated with improved survival in patients with peripheral artery disease. J Am Heart Assoc. 2017; 6: e005699 [Erratum in: J Am Heart Assoc. 2019; 8: e002305]. DOI: 10.1161/JAHA.117.005699
  26. Кухарчук В.В., Ежов М.В., Сергиенко И.В.и др. Клинические рекомендации Евразийской ассоциации кардиологов (ЕАК)/ Национального общества по изучению атеросклероза (НОА) по диагностике и коррекции нарушений липидного обмена с целью профилактики и лечения атеросклероза (2020). Евразийский кардиологический журнал. 2020; 2: 6–29 [Kukharchuk V.V., Ezhov M.V., Sergienko I.V. et al. Eurasian association of cardiology (EAC)/ Russian national atherosclerosis society (RNAS, Russia) guidelines for the diagnosis and correction of dyslipidemia for the prevention and treatment of atherosclerosis (2020). Eurasian heart journal. 2020; 2: 6–29 (in Russ.)]. DOI: 10.38109/2225-1685-2020-2-6-29
  27. Reynolds K., Mues K.E., Harrison T.N. et al. Trends in statin utilization among adults with severe peripheral artery disease including critical limb ischemia in an integrated healthcare delivery system. Vasc Med. 2020; 25 :3–12. DOI: 10.1177/1358863X19871100
  28. Moore J.L., McFarland G.E., Novak Z. et al. Effects of statin and antiplatelet therapy noncompliance and intolerance on patient outcomes following vascular surgery. J Vasc Surg. 2020; 71: 1358–69. DOI: 10.1016/j.jvs.2019.07.063